Canada Markets close in 1 hr 57 mins

Astria Therapeutics, Inc. (ATXS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.0050+0.0350 (+1.18%)
As of 01:42PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close2.9700
Open2.9880
Bid3.0000 x 1300
Ask3.0100 x 2900
Day's Range2.9700 - 3.0400
52 Week Range2.3600 - 12.3600
Volume24,681
Avg. Volume57,203
Market Cap39.094M
Beta (5Y Monthly)1.42
PE Ratio (TTM)N/A
EPS (TTM)-33.6800
Earnings DateMar 09, 2022 - Mar 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.80
  • Business Wire

    Astria Therapeutics Presents New Preclinical Data Showing Differentiated Profile of STAR-0215, in Development for Treatment of Hereditary Angioedema

    BOSTON, July 05, 2022--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, presented new preclinical data that demonstrate STAR-0215’s rapid and durable inhibition of plasma kallikrein in cynomolgus monkeys, supporting the potential for once every three month or longer dosing in humans. The Flash Talks session entitled "STAR-0215, a Long-A

  • Business Wire

    Astria Therapeutics to Present New Preclinical STAR-0215 Data at the European Academy of Allergy and Clinical Immunology 2022 Hybrid Congress

    BOSTON, June 23, 2022--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will share new preclinical data for STAR-0215 in two presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2022 Hybrid Congress which takes place from July 1-3, 2022 in Prague, Czech Republic.

  • Business Wire

    Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

    BOSTON, June 03, 2022--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215 at the upcoming Jefferies Healthcare Conference on Friday, June 10th at 10:30am ET in New York, NY.